Dr Dilip Surana, CMD of Micro Labs Limited, hails tariff shield as a landmark step that strengthens India’s $9 billion pharma exports to the US, meeting nearly half of America’s generic drug demand while easing patient cost burdens. New Delhi/Washington – The India–US bilateral trade
Recent Posts
- France on the Brink: When Public Anger Becomes a Crisis of the State
- The Great Export Shift: How India Rewired Its Global Trade DNA
- Network 7 Media Group Announces the 15th Annual India Leadership Conclave & Power Brand Awards 2026: “Lead or Follow: The New Architecture of Disruption”
- Where Is Gyanesh Kumar Now? The Constitutional Eclipse at Nirvachan Sadan
- India’s 10 Core Economic Engines: An Empirical Breakdown of Growth, Jobs, Trade, and FDI










